Abstract:Advances in cancer immunotherapy have offered new hope for patients with metastatic disease. This unfolding success story has been exemplified by a growing arsenal of novel immunotherapeutics, including blocking antibodies targeting immune checkpoint pathways, cancer vaccines, and adoptive cell therapy (ACT). Nonetheless, clinical benefit remains highly variable and patient-specific, in part, because all immunotherapeutic regimens vitally hinge on the capacity of endogenous and/or adoptively transferred T-effector (Teff) cells, including chimeric antigen receptor (CAR) T cells, to home efficiently into tumor target tissue. Thus, defects intrinsic to the multi-step T-cell homing cascade have become an obvious, though significantly underappreciated contributor to immunotherapy resistance. Conspicuous have been low intralesional frequencies of tumor-infiltrating T-lymphocytes (TILs) below clinically beneficial threshold levels, and peripheral rather than deep lesional TIL infiltration. Therefore, a Teff cell ‘homing deficit’ may arguably represent a dominant factor responsible for ineffective immunotherapeutic outcomes, as tumors resistant to immune-targeted killing thrive in such permissive, immune-vacuous microenvironments. Fortunately, emerging data is shedding light into the diverse mechanisms of immune escape by which tumors restrict Teff cell trafficking and lesional penetrance. In this review, we scrutinize evolving knowledge on the molecular determinants of Teff cell navigation into tumors. By integrating recently described, though sporadic information of pivotal adhesive and chemokine homing signatures within the tumor microenvironment with better established paradigms of T-cell trafficking under homeostatic or infectious disease scenarios, we seek to refine currently incomplete models of Teff cell entry into tumor tissue. We further summarize how cancers thwart homing to escape immune-mediated destruction and raise awareness of the potential impact of immune checkpoint blockers on Teff cell homing. Finally, we speculate on innovative therapeutic opportunities for augmenting Teff cell homing capabilities to improve immunotherapy-based tumor eradication in cancer patients, with special focus on malignant melanoma.

Immune cell migration in inflammation: present and future therapeutic targets

Interstitial leukocyte migration and immune function

Leukocyte trafficking: Can we bring the fight to the tumor?

Immune Cell Migration to Cancer

Dendritic cell migration in inflammation and immunity

Macrophage 3D migration: A potential therapeutic target for inflammation and deleterious progression in diseases

Gut immune cell trafficking: inter-organ communication and immune-mediated inflammation

Immune cell trafficking: a novel perspective on the gut-skin axis

Phosphoinositide Signaling in Immune Cell Migration

Novel mechanistic concepts for the control of leukocyte transmigration: specialization of integrins, chemokines, and junctional molecules

Leukocyte-based delivery systems for enhanced nanotheranostics of inflammation and cancer

More Than Just Attractive: How CCL2 Influences Myeloid Cell Behavior Beyond Chemotaxis

In vivo imaging and quantitative analysis of leukocyte directional migration and polarization in inflamed tissue

Lymphocyte Homing and Homeostasis

Atypical chemokine receptors in the immune system

Inhibition of Toll-Like Receptor Signaling as a Promising Therapy for Inflammatory Diseases: A Journey from Molecular to Nano Therapeutics.

2 integrin activation and signal transduction in leukocyte recruitment

Cell migration: implications for repair and regeneration in joint disease

T-lymphocyte homing: an underappreciated yet critical hurdle for successful cancer immunotherapy

Defects in T Cell Trafficking and Resistance to Cancer Immunotherapy

Immune-mediated inflammatory disease therapeutics: past, present and future